NCT04166656View on ClinicalTrials.gov

Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

PHASE3RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

September 15, 2022

Primary Completion Date

September 30, 2028

Study Completion Date

October 31, 2028

Conditions
Splenectomy
Interventions
BIOLOGICAL

Trumenba®

Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.

BIOLOGICAL

Bexsero®

Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe

Trial Locations (1)

75014

RECRUITING

I-REIVAC/CIC1417 Cochin Hospital, AP-HP, Paris

Sponsors
All Listed Sponsors
collaborator

EUCLID Clinical Trial Platform

OTHER

collaborator

Recherche Clinique Paris Descartes Necker Cochin Sainte Anne

OTHER

collaborator

CIC 1417 Cochin-Pasteur

OTHER

collaborator

Innovative clinical research in vaccinologie (I-REIVAC)

UNKNOWN

collaborator

Institut Pasteur

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04166656 - Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia. | Biotech Hunter | Biotech Hunter